Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

11.36 -0.03 (-0.26%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Lucky Day ↗

March 21, 2022

Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund.

Via Talk Markets

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

Novocure Q4 Earnings Miss Street View, New Data Shows TTFields Initiates Downstream Anti-Tumor Response ↗

February 24, 2022

A new study published in the Journal of Clinical Investigation (JCI) finds treatment with Novocure Ltd's (NASDAQ: NVCR) Tumor Treating Fields (TTFields) mediated...

Via Benzinga

Bionano Stock Looks to Have a Monster Comeback in Its Future ↗

February 17, 2022

Bionano's Saphyr appears to be able to help doctors treat leukemia, and the adoption of its device is growing rapidly.

Via InvestorPlace

Where NovoCure Stands With Analysts ↗

February 08, 2022

NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Give peace a chance ↗

February 15, 2022

Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 09, 2022

Gainers Bone Biologics (NASDAQ:BBLG) shar...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2022 ↗

February 08, 2022

Upgrades According to Consumer Edge Research, the prior rating for The Hain Celestial Group Inc (NASDAQ:HAIN) was changed from Equal-Weight to Overweight. For the second...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

World Markets News ↗

January 20, 2022

Today oil and gas inventories were seen as higher than expected while potential prices fell, both bullish.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 ↗

January 20, 2022

Upgrades For W.P. Carey Inc (NYSE:WPC), B...

Via Benzinga

Cramer Gives His Opinion On Novocure, InMode, Virgin Galactic And More ↗

January 12, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Atkore (NASDAQ:

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 06, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

Stocks That Hit 52-Week Lows On Wednesday ↗

January 05, 2022

Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a...

Via Benzinga

Start Of 2022 ↗

January 03, 2022

Mohammed El Erien predicts that the Fed will be slamming on the brakes this year.

Via Talk Markets

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Happy New Year - Sunday Edition ↗

January 02, 2022

Starting a new year - we look at tech, pharma and mining stocks and their goings-on.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗

January 03, 2022

Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...

Via Benzinga

Market Trend: Erratic And Unreliable ↗

December 29, 2021

Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is.

Via Talk Markets

Plague Year Reversal ↗

December 21, 2021

Just in time for Christmas, the market decided to go up today pretty much across the board.

Via Talk Markets

Inflation Surge ↗

December 10, 2021

Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high.

Via Talk Markets

recession in 2022? ↗

December 06, 2021

China has cut its reserve requirement for lending by 50% giving a $188 bn boost to its market.

Via Talk Markets

Topics Economy

Charms Of China ↗

December 03, 2021

Today the global stock market rout was pretty awful.

Via Talk Markets

Is It Time to Buy the 3 Worst-Performing Growth Stocks of 2021? ↗

December 03, 2021

This year's big pullbacks are more the result of a raucous 2020, and less an indictment of these companies' prospects.

Via The Motley Fool

Topics Stocks

Tuesday Markets Review ↗

November 30, 2021

The oil price did not fall as expected over the White House release of 50 mn bbls of oil.

Via Talk Markets

Tuesday Markets Coverage ↗

November 23, 2021

GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears.

Via Talk Markets

Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial ↗

November 15, 2021

Novocure Ltd (NASDAQ: NVCR) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and...

Via Benzinga

What's the Outlook for Novocure? ↗

November 13, 2021

There's a lot riding on clinical studies of the company's tumor treating fields product.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

NovoCure Limited - Ordinary Shares (NQ:NVCR)

Headline News about NovoCure Limited - Ordinary Shares

Starting at $3.75/week.

Subscribe Today